Related Experiment Video
Updated: Mar 16, 2026
08:39
Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides
Published on: September 16, 2020
8.6K
Targeting Mitochondria in Cardiovascular Diseases.
Filomena S G Silva, Rui F Simoes, Renata Couto
1CNC - Center for Neuroscience and Cell Biology, University of Coimbra, UC Biotech Building, Biocant Park, 3060-197 Cantanhede, Portugal.
Current Pharmaceutical Design
|August 24, 2016
Summary
New strategies targeting mitochondria show promise for treating cardiovascular diseases (CVDs). While current mitochondrial therapies are limited, emerging approaches offer hope for effective CVD prevention and treatment.
Area of Science:
- Mitochondrial medicine
- Cardiovascular pharmacology
- Biomedical research
Background:
- Cardiovascular diseases (CVDs) are a leading cause of death globally.
- Mitochondria are crucial for cardiac function and are a target for cardioprotective drugs.
- Current mitochondrial therapies for CVDs are limited by bioavailability and toxicity, with many still in pre-clinical or clinical trials.
Purpose of the Study:
- To review cardiac mitochondrial effects of targeted and non-targeted antioxidants and pharmacological agents.
- To highlight novel mitochondrial-targeting strategies for CVD treatment.
- To discuss the strengths and weaknesses of existing and emerging cardioprotective approaches.
Main Methods:
- Literature search using PubMed queries.
- Review of cardiac mitochondrial effects of specific agents (e.g., MitoQ, carvedilol, ranolazine).
- Analysis of new mitochondrial-targeting strategies for CVD.
Main Results:
- Several targeted and non-targeted agents show potential cardioprotective effects.
- New strategies aim to overcome limitations of current approaches like poor bioavailability and toxicity.
- Existing agents have varying efficacy and clinical applicability.
Conclusions:
- Effective clinical therapies targeting mitochondria for CVDs are not yet widespread.
- Novel mitochondrial-targeting strategies represent a promising avenue for future CVD prevention and treatment.
- Further research is needed to translate these strategies into clinical practice.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
19.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
19.4K
01:45Mitochondrial Membranes
17.6K
A single mitochondrion is a bean-shaped organelle enclosed by a double-membrane system. The outer membrane of mitochondria is smooth and contains many porins - the integral membrane transporters. Porins enable free diffusion of ions and small uncharged molecules through the outer mitochondrial membrane but limit the transport of molecules larger than 5000 Daltons. Further, the outer mitochondrial membrane forms a unique structure called membrane contact sites with other subcellular organelles,...
17.6K
01:37Mitochondria
21.2K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
21.2K
01:28The Inner Mitochondrial Membrane
5.0K
The inner mitochondrial membrane is the primary site of ATP synthesis. The inner membrane domain that forms a smooth layer adjacent to the outer membrane is called the inner boundary membrane. This domain contains membrane transporters that drive metabolites in and out of the mitochondria. In contrast, the inner membrane network that invaginates into the matrix space is called the cristae membrane. This domain accounts for principle mitochondrial function as it accommodates the protein...
5.0K